Trial reportAmerican journal of respiratory and critical care medicine2020
Renin and Survival in Patients Given Angiotensin II for Catecholamine-Resistant Vasodilatory Shock. A Clinical Trial.
4 registry-linked trialsOpen access · hybridAbstract readClinical Trial
In one paragraph
Trial report in American journal of respiratory and critical care medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 129 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
129citing papers in PubMed, 3 pooled it
14.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NCT04901169 phase2 / phase3active not recruitingnot on this mapstarted 2022, after this paper: background citation
Angiotensin II in Liver Transplantation (AngLT-1): A Pilot Randomized Controlled Trial
A Randomized Controlled Pilot Trial of Angiotensin II Versus Vasopressin as Second-line Vasopressor in the Treatment of Septic Shock
DPP3, Angiotensin II, and Renin Kinetics in Sepsis (DARK-Sepsis) Pilot: Serum Biomarkers to Predict Response to Angiotensin II vs. Standard-of-care Vasopressor Therapy in the Treatment of Septic Shock, a Randomized Controlled Pilot Trial
Angiotensin II Stress Test. Renin Kinetics During Treatment of Vasoplegic Shock With Angiotensin II in Relation to Hemodynamic Response to Treatment With Angiotensin II.
Who cites it
129 citing papers in PubMed, 3 syntheses or guidelines pooled it, 221 citations in OpenAlex.
- An overview of reviews of Angiotensin II in distributive shock.BMC anesthesiology · 2026Pooled it
- Predictive enrichment using biomarkers in studies of critically-ill patients with sepsis: a systematic review.Critical care (London, England) · 2025Pooled it
- Non-adrenergic vasopressors for vasodilatory shock or perioperative vasoplegia: a meta-analysis of randomized controlled trials.Critical care (London, England) · 2024Pooled it
- Early multimodal vasopressor strategy in septic shock: results of the TRICYCLE randomized controlled trial.Critical care (London, England) · 2026Trial
- An index of the initial blood pressure response to angiotensin II treatment and its association with clinical outcomes in vasodilatory shock.Critical care (London, England) · 2025Trial
- Stronger association of intact angiotensinogen with mortality than lactate or renin in critical illness: post-hoc analysis from the VICTAS trial.Critical care (London, England) · 2024Trial
- ACE inhibitors and angiotensin receptor blockers differentially alter the response to angiotensin II treatment in vasodilatory shock.Critical care (London, England) · 2024Trial
- Initiating angiotensin II at lower vasopressor doses in vasodilatory shock: an exploratory post-hoc analysis of the ATHOS-3 clinical trial.Critical care (London, England) · 2023Trial
- Article
- Role of Angiotensin II as a Vasoactive Agent to Treat Distributive Shock With a Focus on Preliminary Data in Pediatric-Aged Patients.Paediatric anaesthesia · 2026Review
- Vasoplegia in Cardiac Surgery and Mechanical Circulatory Support: From Cardiopulmonary Bypass to Advanced Circulatory Support Devices.Journal of cardiovascular development and disease · 2026Review
- Impact of Using Biomarkers in Eligibility Criteria in Acute Kidney Injury Randomized Controlled Trials: A Systematic Review and Methodological Meta-Analysis.Kidney medicine · 2026Article
- Pediatric sepsis-associated acute kidney injury: leveraging pathophysiology for risk stratification and identification of treatable traits.Pediatric nephrology (Berlin, Germany) · 2026Review
- Update on sepsis treatment.Journal of intensive care · 2026Review
- External Validation, Molecular Signatures, and Therapeutic Relevance of Pediatric Sepsis-Associated Acute Kidney Injury Subphenotypes.Critical care medicine · 2026Observational
- Current and future strategies aiming at reducing catecholamine exposure in septic shock.Critical care (London, England) · 2026Review
- Effects of septic shock vasopressors on the fitness of Escherichia coli.Scientific reports · 2026Article
- Profiling of Both Dipeptidyl Peptidase III and Renin Reveals Higher Mortality in Septic Shock.Research square · 2026Article
- Managing sepsis in the era of precision medicine: a narrative review.Acute and critical care · 2026Article
- Toward endotype-guided renin-angiotensin-aldosterone system modulation in septic shock.Critical care (London, England) · 2026Article
69 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on byReply to Picod2021
Authors and funding
15 authors at 13 institutions in 4 countries.
Rinaldo BellomoCentre for Integrated Critical Care, Department of Medicine & Radiology, The University of Melbourne, Melbourne, Victoria, Australia.
Lui G ForniIntensive Care Unit, Royal Surrey Hospital Foundation Trust, Guildford, United Kingdom.
Laurence W BusseDivision of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, and.
Michael T McCurdyDivision of Pulmonary & Critical Care Medicine, School of Medicine, University of Maryland, Baltimore, Maryland.
Kealy R HamDepartment of Critical Care, Regions Hospital, University of Minnesota, St. Paul, Minnesota.
David W BoldtDivision of Critical Care, Department of Anesthesiology and Perioperative Medicine, University of California, Los Angeles, Los Angeles, California.
Johanna HästbackaDivision of Intensive Care Medicine, Department of Perioperative, Intensive Care and Pain Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Ashish K KhannaDepartment of Anesthesiology, Section on Critical Care Medicine, School of Medicine, Wake Forest University, Winston-Salem, North Carolina.
Timothy E AlbertsonDivision of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, School of Medicine, University of California-Davis, Northern California Health System, Mather, California.
James TumlinRenal Division, Department of Medicine, Emory University Medical Center, Emory University, Atlanta, Georgia.
Kristine StoreyLa Jolla Pharmaceutical Company, San Diego, California.
Damian HandisidesLa Jolla Pharmaceutical Company, San Diego, California.
George F TidmarshLa Jolla Pharmaceutical Company, San Diego, California.
Lakhmir S ChawlaLa Jolla Pharmaceutical Company, San Diego, California.
Marlies OstermannDepartment of Critical Care, Guy's & St. Thomas' Hospital, King's College London, London, United Kingdom.
La Jolla Pharmaceutical (United States) · USEmory University · USOutcomes Research Consortium · USPalo Alto University · USRegions Hospital · USRoyal Surrey County Hospital · GBSan Francisco VA Medical Center · USSt Thomas' Hospital · GBThe University of Melbourne · AUUniversity of California, Los Angeles · USUniversity of Helsinki · FIUniversity of Maryland, Baltimore · USVA Northern California Health Care System · US
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
AgedAngiotensin IIBiomarkersCatecholaminesFemaleHumansMaleMiddle AgedPredictive Value of TestsReninShockVasoconstrictor AgentsAngiotensin IIBiomarkersCatecholaminesReninVasoconstrictor Agentsangiotensin-converting enzyme defectangiotensin Idistributive shockrenin–angiotensin–aldosterone system
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
NCT04901169ClinicalTrials.gov
NCT05193370ClinicalTrials.gov
NCT05824767ClinicalTrials.gov
NCT06539234ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.